Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SBMI - Siguiri Basin Mining, Inc. (Pink Sheets:SBMI) Addresses Share Structure; Announces No Reverse Split Planned
May 14, 2007 10:28:00 AM
CORAL GABLES, FL -- (MARKET WIRE) -- 05/14/07 -- Siguiri Basin Mining, Inc. (PINKSHEETS: SBMI) has directed that its stock structure information be updated to reflect the total outstanding share amount of 705 million shares. The Company believes the current share price does not adequately reflect the value of its joint venture with Consolidated Mining and Minerals. However, at this time the Company has decided not to affect a reverse split; instead, SBMI will continue to concentrate its efforts on achieving producer status in the coming weeks.
The Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward looking. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statement.
ABOUT THE COMPANY
Siguiri Basin Mining, Inc. (PINKSHEETS: SBMI) is a mineral exploration and development company focused on achieving producer status. The Company's targets are precious metal properties in stable countries within opportunity rich West Africa, Central and South America with near term production capabilities. www.sbmining.com
For further information contact:
Rich Kaiser
YES International
1-800-631-8127
001-757-306-6090 (outside North America)
Email: yes@yesinternational.com
"So I'm feel'n pretty lucky at the moment"...
SELL
LOL
great Johno, a lady friend was dreaming that she found one the other day, then later in the day found one.
makes ya smile
SCII - Stem Cell Therapy International, Inc. Approved for OTC Bulletin Board and Commenced Trading on May 11, 2007 With Ticker Symbol "SCII"
May 14, 2007 9:37:00 AM
TAMPA, FL -- (MARKET WIRE) -- 05/14/07 -- Stem Cell Therapy International, Inc. (OTCBB: SCII), a leading stem cell research company operating international affiliate treatment clinics, announced today that its common stock has been approved for quotation on the National Association of Security Dealers (NASD) OTC Bulletin Board (OTCBB) commencing on May 11, 2007. The Company's ticker symbol is "SCII" and the Company's web site is www.SCTIcorp.com.
"Our listing on the OTCBB is a significant achievement for us," said Calvin Cao, president and CEO of Stem Cell Therapy International. "By being approved for quotation on the OTCBB we are executing our growth strategy to attract a wider range of investors in the U.S. and overseas. We are on a 'fast track' to revenue by keeping our focus on expanding our international treatment clinics, currently in three countries, to an additional seven countries. This is in accordance with our mission of creating the world's largest network of stem cell treatment facilities in conjunction with leading hospitals and cutting-edge medical professionals. Our unique business model of developing patented and patent pending stem cell solutions, in combination with our opening of affiliate treatment clinics worldwide, is what sets us apart from other stem cell companies that are limited to strictly research and development, but lacking a distribution network to generate revenues for their shareholders," stated CEO Calvin Cao.
"Stem cell transplantation therapy is a field of medicine which uses techniques and technologies that work by replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. Stem Cell Therapy International's proprietary treatments offer the dramatic health benefits of organ transplantation, while at the same time eliminating the need for major surgery, eliminating the time and pain associated with surgical recovery, eliminating the risk of organ transplant rejection, and providing a far less expensive solution than is currently available with traditional medical methods. These are just a few of the many reasons why stem cell treatments are thought to be the most promising development in medicine in the last 100 years. While many other stem cell companies have decided to postpone sales revenues until the FDA approves treatments for use in the USA, which could take several years, Stem Cell Therapy International has already begun to generate revenues in three countries where stem cell treatments are currently approved. To further increase our revenues while waiting for USA approvals we are in the process of expanding our clinics to another seven countries where stem cell treatments are already approved," stated Cao.
The validity and importance of stem cell treatment options has recently gained public and governmental support with the enactment of Proposition 71 in California, creating a fund of $3 billion for stem cell research, followed by funding appropriations in other states such as New Jersey, Massachusetts, Connecticut, Illinois and Wisconsin. Unlike many other stem cell companies whose business model is negatively impacted by a lack of federal funds for embryonic stem cell research, Stem Cell Therapy International is developing stem cell solutions based upon umbilical cord blood, which is not subject to the moral, legal and ethical controversy surrounding embryonic stem cell research.
About Stem Cell Therapy International
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company's website www.SCTIcorp.com
Forward-Looking Statements. This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.
For more information, please contact:
Stem Cell Therapy International, Inc.
Investor Relations
Calvin C. Cao
Chairman and CEO
T: 813-600-4088
E: calvin@SCTIcorp.com
New Clinic Partners, Licensing and Joint Ventures
Gerald R. Newman, Esq.
T: 310-652-6642
E: gnewman@mergerslawyer.com
UTVG - Universal Travel Group Q1 '07 Revenue Up 811% to $6.9 M
Net Income $653,610 or $0.02 per share
May 14, 2007 9:24:00 AM
LOS ANGELES, Calif. and SHENZHEN, China, May 14 /PRNewswire-FirstCall/ -- Universal Travel Group (OTC Bulletin Board: UTVG) which operates through its wholly-owned subsidiary, Shenzhen Yu Zhi Lu Aviation Service Company Ltd. (YZL), a leading air travel agency in Southern China, announced financial results for the first quarter of fiscal year 2007.
For the first quarter, Universal Travel reported $6.9 million in revenue, up 811% from $764,504 for the comparable quarter in fiscal year 2006. The increase is attributed to a rising customer base as well as the acquisition of Speedy Dragon and the addition of air cargo transportation and hotel booking services businesses during the quarter.
Net income was $653,610, or $0.02 per share, for the first quarter '07, up from $460,329 a year ago. Net income was adversely impacted by the second half of the company's stock compensation charge reported last fiscal year. This represents Universal's last expense in connection with this plan.
The company reported gross profit of $2.2 million and a gross profit margin of 32.4% for the quarter. Income from operations was $870,308 for the quarter.
Chairman and CEO Ms. Jiangping Jiang said, "This was a strong quarter for Universal Travel Group. We are very pleased with the increase in revenue for the quarter. Assets for the quarter were $12.5 million, up from $7.5 million for the comparable quarter a year ago. The increase in assets includes approximately $3 million in goodwill associated with the Speedy Dragon acquisition. We expect our assets to continue to grow as we complete the acquisition of Shanghai Lanbao, which we announced two weeks ago.
"Looking ahead, we expect further growth for our company. With the acquisition of Speedy Dragon and Shanghai Lanbao we will have added two new operating segments for the company that will provide an additional boost in revenue for the upcoming fiscal year. Our recent appointment of Richard Cohen to our board of directors cements our ties to our U.S. shareholder base. We are very pleased to welcome Richard to our team."
The financial statements follow.
Universal Travel will hold a conference call with key members of its management team today at 11:00 a.m. Eastern Time. The conference call will cover the company's first quarter earnings results. A question-and-answer session will follow.
To participate, call (877) 407-9205 after 10:50 a.m. Eastern Time today. International callers should dial (201) 689-8054. While in conference, if callers should experience any difficulty or require operator assistance, they can press the (*) followed by the (0) button. This will call an operator to the line.
A live webcast of the call will be available at http://www.vcall.com/IC/CEPage.asp?ID=117064 and http://www.hawkassociates.com/utvgmore.aspx. It will be archived until August 15.
About Universal Travel Group
Universal Travel Group, through its wholly-owned subsidiary, Shenzhen Yu Zhi Lu Aviation Service Company Ltd., is engaged in providing reservation, booking, and domestic and international travel and tourism services throughout China. The company's core services include booking services for air tickets, hotels, and restaurants, tour routing for customers and an air cargo division. The company's goal is to become China's leading travel services provider. For more information, visit http://www.chutg.com.
A profile for investors can be accessed at
http://www.hawkassociates.com/utvgprofile.aspx. For investor relations
information regarding Universal Travel Group, contact Jacalyn Guo at (310)
443-4151, e-mail: Jacalyn@chutg.com, or contact Frank Hawkins or Julie
Marshall, Hawk Associates, at (305) 451-1888, e-mail: info@hawkassociates.com.
An online investor kit including press releases, current price quotes, stock
charts and other valuable information for investors may be found at
http://www.hawkassociates.com and http://www.americanmicrocaps.com. To receive
these releases via e-mail, subscribe at
http://www.hawkassociates.com/email.aspx.
Forward-looking Statement:
The statements in these news releases contain forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such forward-looking statements involve certain risks, assumptions and uncertainties. In each case actual results may differ materially from such forward-looking statements. Any statements regarding targets for future results are forward-looking and actual results may differ materially. These are the company's targets, not predictions of actual performance.
UNIVERSAL TRAVEL GROUP, INC.
CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31,
2007 2006
Gross Revenues - Net $ 6,961,140 $ 764,504
Cost of services 4,705,678 -
Gross Profit 2,255,462 764,504
Selling, General and administrative expenses 751,794 228,456
Stock Based Compensation 633,360 -
1,385,154 228,456
Income from operations 870,308 536,048
Other (Income) Expense
Interest income 6,419
Other Income 10,100 -
Interest expense (980) (904)
Total Other Income (Expense) 9,120 5,515
Income before income taxes 879,428 541,563
Provision for income taxes 225,818 81,234
Net income $ 653,610 $ 460,329
UNIVERSAL TRAVEL GROUP, INC.
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2007 AND DECEMBER 31, 2006
ASSETS 2007 2006
Current Assets
Cash and cash equivalents $ 1,354,039 $ 1,043,555
Accounts Receivable 1,582,586 18,788
Acquisition Deposit - 2,881,823
Loans Receivable 1,260,950 661,158
Due from Shareholders 54,173 -
Trade Deposit 872,793 959,605
Advances 2,805,787 1,831,558
Refundable Deposits 420,329 34,004
Prepaid expenses and
other receivables 435,207 31,842
Total Current Assets 8,785,864 7,462,333
Property & equipment, net 74,391 51,555
Intangible assets 42,254 49,938
Goodwill 3,621,513
Total Assets $ 12,524,022 $ 7,563,826
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Notes payable - Bank $ 1,148,380 $ -
Accounts payable and accrued expenses 4,002,492 3,391,229
Income tax payable 225,761 263,850
Total Current Liabilities 5,376,633 3,655,079
Stockholders' Equity
Common stock, $.001
par value, 70,000,000
shares authorized,
34,934,285 issued and outstanding 34,934 30,450
Additional paid in capital 2,910,929 332,013
Other comprehensive income 105,443 103,811
Retained earnings 4,096,083 3,442,473
Total Stockholders' Equity 7,147,389 3,908,747
Total Liabilities
and Stockholders' Equity $ 12,524,022 $ 7,563,826
Universal Travel Group
10940 Wilshire Blvd. Suite 1600
Los Angeles, CA 90024
Contact: Jacalyn Guo
e-mail: : Jacalyn@chutg.com
Phone: (310) 443-4151
www.chutg.com
Investor Relations Contact:
Hawk Associates, Inc.
Frank Hawkins and Julie Marshall
Phone: (305) 451-1888
E-mail: info@hawkassocites.com
http://www.hawkassociates.com
SOURCE Universal Travel Group
----------------------------------------------
Jacalyn Guo
+1-310-443-4151
Jacalyn@chutg.com of Universal Travel Group; or Investor Relations Contact - Frank Hawkins and Julie Marshall
+1-305-451-1888
info@hawkassocites.com
Beef Recall Includes Arizona: Beef Linked to E. Coli Outbreak
--------------------------------------------------------------------------------
By Michael Amsterdam
May 12, 2007
A Minnesota beef company is voluntarily recalling approximately 117,500 pounds of beef trim products used to make ground beef, due to possible contamination with E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service announced. The recall includes Arizona. The recall comes after an E. coli outbreak that has sickened seven residents in Minnesota, who purchased and ate ground beef from local stores there.
Beef Recall Includes Arizona: Beef Linked to E. Coli Outbreak
While those stores have already removed any potentially contaminated beef from their shelves, today's move greatly expands the scope of the recall. The trim was produced on March 27, 2007, and shipped to distributors and retail outlets in Arizona, Illinois, Iowa, Michigan, Minnesota, Ohio, Virginia and Wisconsin.
***
Because these products later became ground beef sold under many different retail brand names, consumers have been advised to check with their local retailer to determine whether they may have purchased any of the products subject to recall.
The USDA didn't provide further identification of where precisely the questionable beef might have gone, and warned, "Because these products later became ground beef sold under many different retail brand names, consumers should check with their local retailer to determine whether they may have purchased any of the products subject to recall."
***
E. coli 0157:H7 is a potentially deadly strain of bacterium. Symptoms of E. coli include stomach cramps that may be severe and diarrhea that may turn bloody within one to three days. E. coli can sometimes lead to complications including kidney failure.
The USDA urges all consumers to thoroughly cook their beef, because high temperatures kill the bacteria.
thnx, found more but just waiting till NITE gets done with the bs before I nibble.
CYRR was SKHR ...
Jan. 31, 2005 the trading symbol for the company has changed from SKHR to CYRR
Publish Date : 9/16/2005 6:34:00 PM
Canary Resources Inc. ("Canary"), a coalbed methane (CBM) company, announces that it has closed a private placement for gross proceeds of US$7,250,000. Investors in this placement include a leading European institution. Funds raised from the placement will be used for drilling and development of CBM in the Eastern Forest City Basin in Kansas and Missouri, and for general working capital purposes.
The placement comprises 18,125,000 new Class A zero-dividend convertible preferred shares which are convertible into 18,125,000 common shares of Canary, and 9,062,500 warrants, each of which permit the holder to purchase a common share of Canary for $1.00 for four years, and carry mandatory exercise provisions if Canary common shares trade above $2.00.
re: CYRR -- Canary Resources, Inc.
see a $7k and $30k buy go through.
NITE was at .83 this morn but of course came down
to do what they do.
Address:
18 Augusta Pines Drive
Suite 264E
Spring, TX 77389
USA
Website: http://www.canaryresources.com
Phone: 803-254-7861
Fax: 803-254-9835
Business Description:
Canary Resources Inc. is independent Oil and Natural Gas Company engaged in the acquisition, exploitation, production and development of oil and natural gas properties. Canary has an active leasing program and farm-out agreements covering acreage in Johnson and Miami Counties, Kansas, and in Bates and Cass Counties, Missouri, for which it is the operator. Canary has offices in Houston, Texas, and Stilwell, Kansas.
just a watch... CYRR - Canary Resources Is Negotiating Joint Venture to Drill Additional CBM Gas Wells
May 11, 2007 9:35:00 AM
STILWELL, KS -- (MARKET WIRE) -- 05/11/07 -- Canary Resources Inc. (PINKSHEETS: CYRR) ("Canary") announced that it has entered into negotiations with a private investment group to drill 10 to 15 coal-bed methane gas wells on its wholly owned leases in Kansas and Missouri on a joint venture basis. If negotiations are successful, Canary will be able to step up development in the Eastern Forest City Basin. It is contemplated that the private investment group would acquire up to a 50% working interest in the new wells drilled under the joint venture agreement. Canary would drill the wells near its recently completed Southern Star Central Gas Pipeline interconnect. Canary Operating Corporation would operate the wells and gas gathering services would be provided by Canary Pipeline, Inc. Canary is finalizing the engineering and regulatory testing for the interconnect facility.
Canary has nineteen completed gas wells, presently shut-in pending pipeline connection, with twelve wells adjacent to its Southern Star interconnect. Initial indications from the wells near the tap are positive: all have good gas shows and are expected to be productive wells. Hook-up of the wells is underway, and Canary expects to achieve commercial gas production and start realizing transportation fees in the second quarter of 2007.
Canary Resources Inc. is an independent Oil and Natural Gas Company engaged in the acquisition, exploitation, production and development of oil and natural gas properties in Johnson and Miami Counties, Kansas, and in Bates and Cass Counties, Missouri, for which it is the operator. Canary has offices in Houston, Texas, and Stilwell, Kansas.
Portions of this document include "forward-looking statements," which may be understood as any statement other than a statement of historical fact. Forward-looking statements contained in this document are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential" and similar expressions. Actual results may vary materially from management's expectations and projections expressed in this document. Certain factors that can affect the Company's ability to achieve projected results include, among others, production variances from expectations, uncertainties about estimates of reserves, volatility of oil and gas prices, the need to develop and replace reserves, the substantial capital expenditures required to fund operations, environmental risks, drilling and operating risks, risks related to exploratory and development drilling, competition, government regulation and the ability of the Company to implement its business strategy. Copyright 2007. All rights reserved Canary Resources Inc.
Image Available: http://www.marketwire.com/mw/frame_mw?attachid=488961
Additional information on Canary Resources Inc. is available from:
investors@canaryresources.com
Or visit the Company's website at http://www.CanaryResources.com
PMCL - Pharm Control Shareholder Update
May 11, 2007 9:45:00 AM
NEW YORK, NY -- (MARKET WIRE) -- 05/11/07 -- The Board of Directors of Pharm Control Ltd. (PINKSHEETS: PMCL) is proud to announce that they have decided to reward patient shareholders with a forward stock split whereby shareholders of record on June 29, 2007 will receive eight (8) new shares for every five (5) shares they hold.
The company intends to proceed with the previously announced stock spin-off of the European distribution company after this dividend is completed.
Pharm Control Ltd. is still in the process of completing its change of transfer agents while awaiting the approval of the new stock symbol by the NASD.
About Pharm Control Ltd.
Pharm Control Ltd. is a leading medicine Research and Development company that is devoted to developing medicines that allow patients to live longer, healthier, and more productive lives. The Company's founders have invested over 10 years of research discovering and developing new and effective non-synthetic medicines to fight disorders and sickness in the modern world.
Safe Harbor Statement
The preceding includes forward-looking statements, which involve known and unknown risks, and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. Any forward-looking statements above are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including, without limitation, competition, intellectual property rights, litigation, needs of liquidity, and other risks detailed from time to time in the company's reports filed with the SEC. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to, continued acceptance of the company's products and services, competition, new products and technological changes, as well as any and all "other risks" associated with business.
Contact:
Pharm Control Ltd.
Eugene Kron
Vice President
Email: pmclinfo@yahoo.com
Tel: (212) 252-4521
PMCL - Pharm Control Shareholder Update
May 11, 2007 9:45:00 AM
NEW YORK, NY -- (MARKET WIRE) -- 05/11/07 -- The Board of Directors of Pharm Control Ltd. (PINKSHEETS: PMCL) is proud to announce that they have decided to reward patient shareholders with a forward stock split whereby shareholders of record on June 29, 2007 will receive eight (8) new shares for every five (5) shares they hold.
The company intends to proceed with the previously announced stock spin-off of the European distribution company after this dividend is completed.
Pharm Control Ltd. is still in the process of completing its change of transfer agents while awaiting the approval of the new stock symbol by the NASD.
About Pharm Control Ltd.
Pharm Control Ltd. is a leading medicine Research and Development company that is devoted to developing medicines that allow patients to live longer, healthier, and more productive lives. The Company's founders have invested over 10 years of research discovering and developing new and effective non-synthetic medicines to fight disorders and sickness in the modern world.
Safe Harbor Statement
The preceding includes forward-looking statements, which involve known and unknown risks, and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. Any forward-looking statements above are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including, without limitation, competition, intellectual property rights, litigation, needs of liquidity, and other risks detailed from time to time in the company's reports filed with the SEC. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to, continued acceptance of the company's products and services, competition, new products and technological changes, as well as any and all "other risks" associated with business.
Contact:
Pharm Control Ltd.
Eugene Kron
Vice President
Email: pmclinfo@yahoo.com
Tel: (212) 252-4521
Scope of pet food recall widens
'Dog biscuits become latest product"
PET FOOD RECALL
Lab results: Melamine not only culprit, research says | Cats appear more vulnerable
China connection : FDA limits Chinese food additive imports | Asian giant grapples with food-safety probe | China admits tainted food link
Probe continues: FDA raids wheat gluten importer | Melamine may not be accident | P&G vows more control of Menu Foods
Science: Pet deaths not easy to solve | Timeline
Recall widens: Cross-contamination prompts new recalls | Premium dry foods recalled | Canadian pet food added to list | Dog biscuits become latest product
Solutions: Owners go organic | No easy answer on feeding Fido | Poison vs. pests | Raw foods are popular, but ...
Backlash: Pet food maker Menu Foods to pay vet bills | Audio: Cat owner sues
Toll: Scores more may have died
By Julie Schmit, USA TODAY
The pet-food recall got bigger Thursday, but federal officials say that looks like the end of it.
Sunshine Mills on Thursday recalled dog biscuits made with allegedly tainted wheat gluten, the fourth pet-food maker in the last week to recall products. Canada's Menu Foods on March 16 started the recall, one of the biggest in history, by recalling more than 60 million cans and pouches of wet cat and dog food.
Sunshine, like Menu and the other pet-food makers, is believed to have received wheat gluten from China containing melamine, a chemical used as a fertilizer in Asia but not allowed in food in the USA.
The Food and Drug Administration said Thursday that it had tracked all the suspect wheat gluten and knew of no other companies likely to do recalls.
Menu Foods, however, extended its recall to include another month of production — just six days after it reassured consumers that all non-recalled Menu products were safe. Menu's recall, covering more than 90 brands, now includes products made from Nov. 8, 2006 to March 6, 2007 — not starting Dec. 3, 2006. No new brands joined the recall, but 20 new varieties of those brands did.
FIND MORE STORIES IN: Food and Drug Administration | Menu | Chemnutra | Sunshine Mills
Menu spokesman Sam Bornstein says the extension was necessary given that Menu got wheat gluten from Las Vegas importer ChemNutra, and ChemNutra said Tuesday that its shipments from the suspected Chinese supplier commenced Nov. 9, 2006.
The other companies that recalled product, ChemNutra has said, purchased much smaller amounts starting in January.
Menu, which makes wet food for leading brands and private labels, expects most of the additional products to have already been pulled from store shelves. It requested on March 24 that retailers remove all affected varieties of Menu's recalled products, regardless of date code.
Sunshine, of Red Bay, Ala., recalled biscuits sold under its own brands, including Nurture, Lassie and Pet Life, and private labels, including Wal-Mart's Ol'Roy.
Separately, the FDA warned consumers not to use American Bullie A.B. Bull Pizzle Puppy Chews and Dog Chews manufactured and distributed by T.W. Enterprises because they have the potential to be contaminated with the salmonella bacteria.
And dont forget to add the cyanuric acid,
Tainted pet food: Lab says melamine not only culprit
Updated 18h 25m ago | Comments 45 | Recommend 18 E-mail | Save | Print | Reprints & Permissions |
PET FOOD RECALL
Lab results: Melamine not only culprit, research says | Cats appear more vulnerable
China connection : FDA limits Chinese food additive imports | Asian giant grapples with food-safety probe | China admits tainted food link
Probe continues: FDA raids wheat gluten importer | Melamine may not be accident | P&G vows more control of Menu Foods
Science: Pet deaths not easy to solve | Timeline
Recall widens: Cross-contamination prompts new recalls | Premium dry foods recalled | Canadian pet food added to list | Dog biscuits become latest product
Solutions: Owners go organic | No easy answer on feeding Fido | Poison vs. pests | Raw foods are popular, but ...
Backlash: Pet food maker Menu Foods to pay vet bills | Audio: Cat owner sues
Toll: Scores more may have died
By Elizabeth Weise, USA TODAY
Melamine combined with a related chemical — rather than melamine alone — likely caused the kidney damage in pets that ate tainted food, one lab investigating the case has found.
The finding by a laboratory in Ontario, Canada, appears to substantiate many scientists' theory that the melamine found in wheat gluten and rice protein concentrate used in recalled pet food did not fully explain the foods' apparent toxic effects on some animals that ate it.
STORY: Poisoned pet food seems to hit cats harder
The other chemical, cyanuric acid, can be produced during the making of melamine.
Used in pool cleaning, it has also been found in samples of recalled pet food.
FIND MORE STORIES IN: James Kapin
A team at the University of Guelph showed crystals formed in the kidneys of pets that ate food with the tainted ingredients are close to 50% melamine and 50% cyanuric acid.
"We took some ordinary cat urine and added three drops of melamine and three drops of cyanuric acid, and we got the identical crystals that we see in the kidneys" of the affected cats, said team leader Brent Hoff, a clinical toxicologist and pathologist at the university's Animal Health Laboratory.
Previous research had found melamine alone to be relatively non-toxic. It is used to make plastic.
The formation of these crystals in the kidneys appears to be the primary cause of renal failure in the affected animals, said Wilson Rumbeiha, a toxicologist at Michigan State University who is reviewing pathology reports on animal deaths related to melamine.
The FDA says melamine was added to two food ingredients, wheat gluten and rice protein concentrate, because it is high in nitrogen and makes the grain product look as if it is higher in protein — and therefore worth more — than it actually is. The ingredients were imported from China.
Pure melamine makes clear, rectangular or needle-like crystals. The melamine-cyanuric acid mix forms crystals that are round and yellow to dark brown, said Hoff.
Melamine is composed of carbon, hydrogen and nitrogen. In China, it is often made from coal, said James Kapin, a member of the American Chemical Society's chemical health and safety committee.
The coal is turned to a gas, and nitrogen-rich compounds are extracted from it. After more steps, the end result is melamine.
Melamine and cyanuric acid are chemically very closely related, said Kapin. So cyanuric acid could be created at several points in the processing of melamine.
As melamine prices have risen, melamine scrap may been substituted for pure melamine.
The Chinese company that sold the tainted wheat gluten had advertised for melamine scrap on websites before the pet-food recall.
"You will get em when we get em."
And I might add...
tdouthouse
never gave me the post slpit shares from last time.
go figure.
MTPM - MitoPharm to Emphasize its Focus on Promoting Health and Vitality Through Improving the Function of Mitochondrial
MitoPharm Corporation (MTPM) (the "Company") is pleased to announce further to its news release of March 9th, 2007, MitoPharm, on January 2007 announced its merger with HerbalPharm, Inc., a Washington company, changed its name to emphasize its focus on promoting health and vitality through improving the function of mitochondria. Mitochondrial decay is a current and popular theory as a leading cause of aging. www.mitopharm.com
The Company's key products, RESTORADE(TM) and STAMINA SOLUTIONS(TM), contain a proprietary compound that, under scientific research, demonstrated the ability to reverse mitochondrial decay due to aging. Mitochondria are primarily responsible for the cellular conversion of food molecules, in the presese of oxygen, to usable energy as well as for playing vital roles in various metabolic tasks and in cellular generation.
The RESTORADE and STAMINA SOLUTIONS products are the result of over 15 years of research and development at Hong Kong University of Science and Technology (HKUST), a founding shareholder of MitoPharm. The research and development is led by Dr. Robert Ko, Associate Professor of the Biochemistry Department at HKUST, also a founding shareholder of MitoPharm. HKUST is a world-class research university ranked # 60 worldwide by the Newsweek Magazine.
About the Company
MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST"). At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain. www.ust.hk
MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active. With its products (to be marketed under MITOPHARM(TM)) MitoPharm believes that it is positioned to become an important producer and supplier in the biotech products industry. www.mitopharm.com
Forward-Looking Statements
This news release includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the Company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our ability to obtain contracts with suppliers of raw materials and distributors of our products; (2) the risks inherent in the mutual performance of such supplier and distributor contracts (including our production performance); (3) our ability to protect and defend our proprietary technology; (4) our ability to secure and retain management capable of managing growth; (5) our ability to raise necessary financing to execute the Company's business plans; and (6) the our ability to comply with all applicable federal, state and local government and international rules and regulations.
Mogul IR
Robert Adams, 713-401-9333
radams@mogulir.com
Source: Business Wire (May 8, 2007 - 8:12 AM EDT)
News by QuoteMedia
www.quotemedia.com
NCFC (was FGFC) - NEW CAPITAL FUNDING CORPORATION Announces Its Direction for Its Wholly Owned Brand BuySellMerge.com
NEW YORK, NY -- (MARKET WIRE) -- 05/08/07 -- NEW CAPITAL FUNDING CORPORATION (PINKSHEETS: NCFC) announced today that it will re-launch its wholly owned Brand BuySellMerge.com as a very viable eCommerce Website generating revenues as previously stated by previous management.
NEW CAPITAL Funding Corp. current and previous management have indicated they ran into numerous challenges in getting the BuySellMerge.com Portal off the ground and is looking into this Brand with a different launch strategy. The company still intends to launch and generate revenues and Deals from this Brand. NCFC is currently negotiating the Acquisition of and Investment in an existing Portal that has a proven track record with current revenue. The Portal has the potential to grow its revenues tenfold within the first year of its acquisition utilizing proven Internet Marketing Strategies. NCFC has made its offer for the Portal on May 3, 2007 and is awaiting the final contract from the Seller.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Contact:
NEW CAPITAL Funding Corp.
Investor Relations
Tel: 1-212-363-4334
Fax: 1-212-658-9539
I like it.
MTPM was HBPM (2/1 F/S) then HBLP fwiw
MTPM - MitoPharm Corporation, Inc. Discovers Biochemical Properties of Schisandrin B
Schisandra fruit has been documented in Traditional Chinese Medicinal (TCM) journals since 1200AD
May 7, 2007 9:36:00 AM
Copyright Business Wire 2007
SEATTLE--(BUSINESS WIRE)--
MitoPharm Corporation, Inc. (Pink Sheets:MTPM), reports today that chronic treatment with Schisandrin B, the precursor of "(-) Schisandrin B," can reverse mitochondrial aging in tissues of the brain, heart, liver and skeletal muscles. MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active.
The newly discovered compound is "(-) Schisandrin B," an isomer of Schisandrin B, which is an active ingredient of Schisandra, the fruit of the Schisandrae Chinensis plant. The use of Schisandra fruit has been documented in Traditional Chinese Medicinal (TCM) journals since 1200AD. Schisandrin B has been studied extensively for the past two decades, mainly in Japan, Korea, Russia and China. It is Dr. Robert Ko (1), Associate Professor of the Biochemistry Department of the Hong Kong University of Science and Technology (the HKUST) (2) that systematically studied the biochemical properties of Schisandrin B, leading to this discovery.
Studies by Professor Robert Ko have corroborated the following remarkable biochemical properties of "(-) Schisandrin B":
Reversing Mitochondrial Decay due to Aging: Mitochondrial decay is hypothesized as the leading cause of aging. The Compound has demonstrated extraordinary ability in reversing mitochondrial decay due to aging. In a research paper recently published in Biogerontology, an authoritative journal for the science of aging, Professor Robert Ko reported that chronic treatment with Schisandrin B, the precursor of "(-) Schisandrin B," can reverse mitochondrial aging in tissues of the brain, heart, liver and skeletal muscles. Further studies by Professor Robert Ko have proved that "(-) Schisandrin B" is more potent than Schisandrin B in counteracting mitochondrial decay with aging.
Synthesis and Regeneration of Cellular or Mitochondrial Glutathione: Glutathione (GSH), a three amino acid peptide, is a natural antioxidant that plays an important role in cellular antioxidant defense against free radicals. GSH not only neutralizes free radicals directly, but also works together with antioxidant enzymes to remove peroxides and thus prevents the oxidation of lipids in the cell. The enhancement of GSH status in the cell, therefore, represents an effective means of curbing free radical reactions, thereby preventing cellular damage. In his studies, Professor Robert Ko verified and explained the effects of "(-) Schisandrin B" and its precursor, Schisandrin B, in enhancing cellular glutathione status of major vital organs including the brain, heart, liver, and skeletal muscles (3 to 18).
Increases the Production of Heat Shock Proteins: The expression of heat shock protein is another fundamental cellular protective mechanism against stress-causing stimuli. In research papers published to-date, Professor Robert Ko have corroborated and provided detailed explanations on the biochemical mechanisms of "(-) Schisandrin B" and its precursor, Schisandrin B, in enhancing cellular Heat Shock Proteins of major vital organs including the heart, brain, liver and skeletal muscles (3 to 18).
The above biological actions are independent of each other, but are mutually augmenting; combined, they produce the following beneficial effects:
-- Anti-aging
-- Stamina improvement
-- Increase in physical exercise endurance and performance
It is the first time that a substance is reported to have the ability to rejuvenate mitochondrial functional capabilities and, at the same time, enhances the cellular self-defense mechanism. Our surveys have indicated that "(-) Schisandrin B" is superior to any existing compound, either natural or synthetic, for the intended applications.
Comprehensive toxicological studies have been conducted with no serious side effects found.
Patent applications for the product formulas have been filed with the USPTO and under the International Patent Convention Treaty. The initial products will be marketed as dietary supplements. As a long term plan, we intend to develop the Compound into pharmaceutical products in compliance with the requirements of the FDA.
(1) Professor Robert KM Ko, a founding shareholder of MitoPharm Corporation, graduated from the University of British Columbia with a PhD degree in Pharmacology. He is a proficient researcher with over 67 research papers, book chapters and articles published. Please visit the MitoPharm website or the HKUST website for a detailed description of Professor Robert Ko and his research interests.
(2) The Hong Kong University of Science and Technology, another founding shareholder of MitoPharm Corporation, is a research university ranked number 60 worldwide by the Newsweek Magazine in 2006. One of the focuses of the University is research and development of Traditional Chinese Medicine (TCM), using the latest in science and technology to verify, explain, and improve on the efficacies of the multiple-ingredient herbal formulas.
(3) Chronic Schisandrin B Treatment Improves Mitochondrial Antioxidant Status and tissue Heat Shock Protein Production in Various Tissues of Young adult and Middle-Aged Rats, Chiu et al., Biogerontology 2006; 7: 199-210
(4) Schisandrin B Protects Against Myocardial Ischemia-Reperfusion Injury by Enhancing Myocardial Glutathione Antioxidant Status, Yim and Ko, Molecular and Cellular Biochemistry 1999; 196: 151-156
(5) Methylenedioxy Group and Cyclooctadiene Ring as Structural Determinants of Schisandrin in Protecting Against Myocardial Ischemia-Reperfusion Injury in Rats, Yim and Ko, Biochemical Pharmacology 1998; 57: 77-81
(6) Schisandrin B Protects Myocardial Ischemia-Reperfusion Injury Partly by Inducing HSP25 and HSP70 Expression in Rats, Chiu and Ko, Molecular and Cellular Biochemistry 2004; 266: 139-144
(7) Structural Determinants of Schisandrin B Which Enhance Mitochondrial Functional Ability and Glutathione Status as Well as Heat Shock Protein Expression in Rat Hearts and H9C2 Cells, Ko and Chiu, Molecular and Cellular Biochemistry 2005; 276: 227-234
(8) (-) Schisandrin B is More Potent Than Its Enantiomer in Enhancing Cellular Glutathione and Heat Shock Protein Production as Well as Protecting Against Oxidant Injury in H9C2 Cardiomyocytes, Chiu et al., Molecular and Cellular Biochemistry 2006; 289: 185-191
(9) Schisandrin B Protects Against Carbon Tetrachloride Toxicity by Enhancing the Mitochondrial Glutathione Redox Status in Mouse Liver, Ip et al., Free Radical Biology & Medicine 1996; 21: 709-712
(10) The Crucial Antioxidant Action of Schisandrin B in Protecting Against Carbon Tetrachloride Hepatotoxicity in Mice: A Comparative Study With Butylated Hydroxytoluene, Ip and Ko, Biochemical Pharmacology 1996; 52: 1687-1693
(11) Methylenedioxy Group as Determinant of Schisandrin in Enhancing Hepatic Mitochondrial Glutathione in Carbon Tetrachloride-Intoxicated Mice, Ip et al., Biochemical Pharmacology 1997; 54: 317-319
(12) Effects of Schisandrin B Pretreatment On Tumor Necrosis Factor-alpha Induced Apoptosis and HSP70 Expression in Mouse Liver, Ip et al., Cell Stress & Chaperones 2001; 6: 44-48
(13) Hepatoprotective Mechanism of Schisandrin B: Role of Mitochondrial Glutathione Antioxidant Status and Heat Shock Proteins, Chiu et al., Free Radical Biology & Medicine 2003; 35: 368-380
(14) Effects of Schisandrin B Enantiomers On Cellular Glutathione and Menadione Toxicity in AML12 Hepatocytes, Chiu et al., Pharmacology 2006; 77: 63-70
(15) Schisandrin B Protects Against Tert-Butylhydroperoxide Induced Cerebral Toxicity by Enhancing Glutathione Antioxidant Status in Mouse Brain, Ko and Lam, Molecular and Cellular Biochemistry 2002; 238: 181-186
(16) Schisandrin B Protects Against Tacrine- and Bis-Tacrine-Induced Hepatotoxicity and Enhances Cognitive Function in Mice, Pan et al., Planta Medica 2002; 68: 217-220
(17) Protective Effect of a Lignan-Enriched Extract of Fructus Schisandrae On Physical Exercise Induced Muscle Damage in Rats, Ko et al., Phytotherapy Research 1996; 10: 450-452
(18) Schisandrin B-Induced Increase in Cellular Glutathione Level and Protection Against Oxidant Injury Are Mediated by the Enhancement of Glutathione Synthesis and Regeneration in AML12 and H9C2 Cells, Chiu and Ko, BioFactors 2006; 26: 221-230
About the Company
MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST").
At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain. www.mitopharm.com or www.ust.hk
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.
Source: MitoPharm Corporation, Inc.
----------------------------------------------
Mogul IR
Investor Relations:
Robert Adams
713-401-9333
radams@mogulir.com
iVoice, Inc. Withdraws SB-2 Registration Statement for 1.1 Billion Shares
May 7, 2007 9:55:00 AM
MATAWAN, NJ -- (MARKET WIRE) -- 05/07/07 -- On May 1, 2007, iVoice, Inc. (OTCBB: IVOI) filed a formal request with the Securities and Exchange Commission for withdrawal of the Company's Registration Statement previously filed on Form SB-2 for the registration of 1,122,178,413 billion shares of common stock issuable upon the conversion of certain convertible debentures (the "Convertible Debentures") previously sold to Cornell Capital Partners, LP ("Cornell") by the Company.
Pursuant to the terms of the Convertible Debentures, the Company is obligated to issue shares of our Class A Common Stock to Cornell upon conversion of the outstanding principal balance and accrued interest of the Convertible Debentures. As a result of the withdrawal of this Registration Statement, Cornell may only sell the Company's shares issued upon the conversion of the Convertible Debentures pursuant to Rule 144. Under the terms of the Convertible Debentures, Cornell may not beneficially own more than 4.9% of our outstanding Class A Common Stock at any one time. However, as Cornell can repeatedly acquire and thereafter sell shares received from the conversion of the Convertible Debentures, restricted by the limitations of Rule 144, these Cornell conversions will have an effect upon the total number of outstanding shares of the Company.
About iVoice, Inc.:
iVoice has determined that the best way to create shareholder value is to implement new business opportunities by distributing shares of spin-offs to the Company's shareholders. The company is also focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
Contact:
Dolores Serafin
iVoice, Inc.
1-732-441-7700
www.ivoice.com
IVOI - iVoice, Inc. Withdraws SB-2 Registration Statement for 1.1 Billion Shares
May 7, 2007 9:55:00 AM
MATAWAN, NJ -- (MARKET WIRE) -- 05/07/07 -- On May 1, 2007, iVoice, Inc. (OTCBB: IVOI) filed a formal request with the Securities and Exchange Commission for withdrawal of the Company's Registration Statement previously filed on Form SB-2 for the registration of 1,122,178,413 billion shares of common stock issuable upon the conversion of certain convertible debentures (the "Convertible Debentures") previously sold to Cornell Capital Partners, LP ("Cornell") by the Company.
Pursuant to the terms of the Convertible Debentures, the Company is obligated to issue shares of our Class A Common Stock to Cornell upon conversion of the outstanding principal balance and accrued interest of the Convertible Debentures. As a result of the withdrawal of this Registration Statement, Cornell may only sell the Company's shares issued upon the conversion of the Convertible Debentures pursuant to Rule 144. Under the terms of the Convertible Debentures, Cornell may not beneficially own more than 4.9% of our outstanding Class A Common Stock at any one time. However, as Cornell can repeatedly acquire and thereafter sell shares received from the conversion of the Convertible Debentures, restricted by the limitations of Rule 144, these Cornell conversions will have an effect upon the total number of outstanding shares of the Company.
About iVoice, Inc.:
iVoice has determined that the best way to create shareholder value is to implement new business opportunities by distributing shares of spin-offs to the Company's shareholders. The company is also focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
Contact:
Dolores Serafin
iVoice, Inc.
1-732-441-7700
www.ivoice.com
MTPM - MitoPharm Corporation, Inc. Discovers Biochemical Properties of Schisandrin B
Schisandra fruit has been documented in Traditional Chinese Medicinal (TCM) journals since 1200AD
May 7, 2007 9:36:00 AM
Copyright Business Wire 2007
SEATTLE--(BUSINESS WIRE)--
MitoPharm Corporation, Inc. (Pink Sheets:MTPM), reports today that chronic treatment with Schisandrin B, the precursor of "(-) Schisandrin B," can reverse mitochondrial aging in tissues of the brain, heart, liver and skeletal muscles. MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active.
The newly discovered compound is "(-) Schisandrin B," an isomer of Schisandrin B, which is an active ingredient of Schisandra, the fruit of the Schisandrae Chinensis plant. The use of Schisandra fruit has been documented in Traditional Chinese Medicinal (TCM) journals since 1200AD. Schisandrin B has been studied extensively for the past two decades, mainly in Japan, Korea, Russia and China. It is Dr. Robert Ko (1), Associate Professor of the Biochemistry Department of the Hong Kong University of Science and Technology (the HKUST) (2) that systematically studied the biochemical properties of Schisandrin B, leading to this discovery.
Studies by Professor Robert Ko have corroborated the following remarkable biochemical properties of "(-) Schisandrin B":
Reversing Mitochondrial Decay due to Aging: Mitochondrial decay is hypothesized as the leading cause of aging. The Compound has demonstrated extraordinary ability in reversing mitochondrial decay due to aging. In a research paper recently published in Biogerontology, an authoritative journal for the science of aging, Professor Robert Ko reported that chronic treatment with Schisandrin B, the precursor of "(-) Schisandrin B," can reverse mitochondrial aging in tissues of the brain, heart, liver and skeletal muscles. Further studies by Professor Robert Ko have proved that "(-) Schisandrin B" is more potent than Schisandrin B in counteracting mitochondrial decay with aging.
Synthesis and Regeneration of Cellular or Mitochondrial Glutathione: Glutathione (GSH), a three amino acid peptide, is a natural antioxidant that plays an important role in cellular antioxidant defense against free radicals. GSH not only neutralizes free radicals directly, but also works together with antioxidant enzymes to remove peroxides and thus prevents the oxidation of lipids in the cell. The enhancement of GSH status in the cell, therefore, represents an effective means of curbing free radical reactions, thereby preventing cellular damage. In his studies, Professor Robert Ko verified and explained the effects of "(-) Schisandrin B" and its precursor, Schisandrin B, in enhancing cellular glutathione status of major vital organs including the brain, heart, liver, and skeletal muscles (3 to 18).
Increases the Production of Heat Shock Proteins: The expression of heat shock protein is another fundamental cellular protective mechanism against stress-causing stimuli. In research papers published to-date, Professor Robert Ko have corroborated and provided detailed explanations on the biochemical mechanisms of "(-) Schisandrin B" and its precursor, Schisandrin B, in enhancing cellular Heat Shock Proteins of major vital organs including the heart, brain, liver and skeletal muscles (3 to 18).
The above biological actions are independent of each other, but are mutually augmenting; combined, they produce the following beneficial effects:
-- Anti-aging
-- Stamina improvement
-- Increase in physical exercise endurance and performance
It is the first time that a substance is reported to have the ability to rejuvenate mitochondrial functional capabilities and, at the same time, enhances the cellular self-defense mechanism. Our surveys have indicated that "(-) Schisandrin B" is superior to any existing compound, either natural or synthetic, for the intended applications.
Comprehensive toxicological studies have been conducted with no serious side effects found.
Patent applications for the product formulas have been filed with the USPTO and under the International Patent Convention Treaty. The initial products will be marketed as dietary supplements. As a long term plan, we intend to develop the Compound into pharmaceutical products in compliance with the requirements of the FDA.
(1) Professor Robert KM Ko, a founding shareholder of MitoPharm Corporation, graduated from the University of British Columbia with a PhD degree in Pharmacology. He is a proficient researcher with over 67 research papers, book chapters and articles published. Please visit the MitoPharm website or the HKUST website for a detailed description of Professor Robert Ko and his research interests.
(2) The Hong Kong University of Science and Technology, another founding shareholder of MitoPharm Corporation, is a research university ranked number 60 worldwide by the Newsweek Magazine in 2006. One of the focuses of the University is research and development of Traditional Chinese Medicine (TCM), using the latest in science and technology to verify, explain, and improve on the efficacies of the multiple-ingredient herbal formulas.
(3) Chronic Schisandrin B Treatment Improves Mitochondrial Antioxidant Status and tissue Heat Shock Protein Production in Various Tissues of Young adult and Middle-Aged Rats, Chiu et al., Biogerontology 2006; 7: 199-210
(4) Schisandrin B Protects Against Myocardial Ischemia-Reperfusion Injury by Enhancing Myocardial Glutathione Antioxidant Status, Yim and Ko, Molecular and Cellular Biochemistry 1999; 196: 151-156
(5) Methylenedioxy Group and Cyclooctadiene Ring as Structural Determinants of Schisandrin in Protecting Against Myocardial Ischemia-Reperfusion Injury in Rats, Yim and Ko, Biochemical Pharmacology 1998; 57: 77-81
(6) Schisandrin B Protects Myocardial Ischemia-Reperfusion Injury Partly by Inducing HSP25 and HSP70 Expression in Rats, Chiu and Ko, Molecular and Cellular Biochemistry 2004; 266: 139-144
(7) Structural Determinants of Schisandrin B Which Enhance Mitochondrial Functional Ability and Glutathione Status as Well as Heat Shock Protein Expression in Rat Hearts and H9C2 Cells, Ko and Chiu, Molecular and Cellular Biochemistry 2005; 276: 227-234
(8) (-) Schisandrin B is More Potent Than Its Enantiomer in Enhancing Cellular Glutathione and Heat Shock Protein Production as Well as Protecting Against Oxidant Injury in H9C2 Cardiomyocytes, Chiu et al., Molecular and Cellular Biochemistry 2006; 289: 185-191
(9) Schisandrin B Protects Against Carbon Tetrachloride Toxicity by Enhancing the Mitochondrial Glutathione Redox Status in Mouse Liver, Ip et al., Free Radical Biology & Medicine 1996; 21: 709-712
(10) The Crucial Antioxidant Action of Schisandrin B in Protecting Against Carbon Tetrachloride Hepatotoxicity in Mice: A Comparative Study With Butylated Hydroxytoluene, Ip and Ko, Biochemical Pharmacology 1996; 52: 1687-1693
(11) Methylenedioxy Group as Determinant of Schisandrin in Enhancing Hepatic Mitochondrial Glutathione in Carbon Tetrachloride-Intoxicated Mice, Ip et al., Biochemical Pharmacology 1997; 54: 317-319
(12) Effects of Schisandrin B Pretreatment On Tumor Necrosis Factor-alpha Induced Apoptosis and HSP70 Expression in Mouse Liver, Ip et al., Cell Stress & Chaperones 2001; 6: 44-48
(13) Hepatoprotective Mechanism of Schisandrin B: Role of Mitochondrial Glutathione Antioxidant Status and Heat Shock Proteins, Chiu et al., Free Radical Biology & Medicine 2003; 35: 368-380
(14) Effects of Schisandrin B Enantiomers On Cellular Glutathione and Menadione Toxicity in AML12 Hepatocytes, Chiu et al., Pharmacology 2006; 77: 63-70
(15) Schisandrin B Protects Against Tert-Butylhydroperoxide Induced Cerebral Toxicity by Enhancing Glutathione Antioxidant Status in Mouse Brain, Ko and Lam, Molecular and Cellular Biochemistry 2002; 238: 181-186
(16) Schisandrin B Protects Against Tacrine- and Bis-Tacrine-Induced Hepatotoxicity and Enhances Cognitive Function in Mice, Pan et al., Planta Medica 2002; 68: 217-220
(17) Protective Effect of a Lignan-Enriched Extract of Fructus Schisandrae On Physical Exercise Induced Muscle Damage in Rats, Ko et al., Phytotherapy Research 1996; 10: 450-452
(18) Schisandrin B-Induced Increase in Cellular Glutathione Level and Protection Against Oxidant Injury Are Mediated by the Enhancement of Glutathione Synthesis and Regeneration in AML12 and H9C2 Cells, Chiu and Ko, BioFactors 2006; 26: 221-230
About the Company
MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST").
At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain. www.mitopharm.com or www.ust.hk
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.
Source: MitoPharm Corporation, Inc.
----------------------------------------------
Mogul IR
Investor Relations:
Robert Adams
713-401-9333
radams@mogulir.com
MDII- MDI Receives Product Order for Implementation at Major U.S. Marine Corps Base
MDI Solution to be Implemented as Part of Base-wide Security Systems Upgrade Project
MDI, Inc. (NASDAQ:MDII), the leading provider of Unified Technology™ solutions for the security industry, today announced that it has received multiple purchase orders for products as part of a base-wide security system implementation project at a major U.S. Marine Corps base. The terms of the award prohibit disclosure of information about the specific locations, the system specifications and the assets being protected.
As one of the most secure military bases in the nation, this state-of-the-art location’s primary focus is combat training, advanced weapons systems, electronic warfare and communications. It is recognized within all U.S. military branches as being a leader in technical innovation and military education. Military innovations at this location pave the way for the future of our armed forces with technological advances for the warfighter and unique battlefield strategies that are vital to the national security of our country.
The base will install the MDI products to upgrade its current security posture to be a more robust and scalable solution than currently in operation. The unique customization and configuration features of MDI’s award-winning ONE™ Unified Technology™ platform will allow base security personnel to manage by exception across multiple layers of protection and detection. As an anomaly, intrusion or occurrence takes place, the automated platform commands a series of pre-configured security events to occur, allowing security managers to command and control building, access and video surveillance functions across multiple remote facilities, aimed at containing or minimizing the threat.
These automated functions tie in to all products that are unified within the platform, allowing for timely human decision-making and response to take place based on the level of threat to people, facilities and assets. The base-wide unification delivered by MDI products will empower security personnel to receive the actionable intelligence necessary to make decisions in real-time, based on the exact levels of security needed, for specific geographic operating locations and perimeters across the base.
About MDI, Inc.
MDI (NASDAQ:MDII) manufactures security technology solutions designed to protect people, facilities and assets. These solutions are unified by ONE Technology. ONE Technology unifies security point products, systems and subsystems into a common management platform. Far beyond the Integrated Security Management software promoted by industry competitors, ONE delivers an open architecture environment that adapts each individual application and device into its platform -- promoting global collaboration as ONE system. The MDI product family currently protects over 8 million alarm points across the globe for many of the world’s most recognized organizations including Microsoft, MBNA Worldwide, John Deere, Pepsi, FBI, TSA, Fidelity Investments, Bureau of Engraving & Printing, American Express, Department of Defense, IRS, Disney, Smithsonian Institution and MIT to name a few. For more information on MDI or its diversified line of security products, please visit www.mdisecure.com.
Forward-Looking and Cautionary Statements
Except for historical information and discussions contained herein, certain statements included in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this document, other than statements of historical fact, that address activities, events or developments that management expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements represent our reasonable judgment on the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “project,” “forecast,” “plan,” “may,” “will,” “should,” “expect” and other words of similar meaning. Investors should not rely on forward-looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the Company’s expectation. Additional information concerning risk factors is contained from time to time in the Company’s SEC filings. The Company expressly disclaims any obligation to update the information contained in this release.
MDI, Inc., San Antonio
Investor Relations Contact:
Richard A. Larsen, 210-582-2664
Richard.Larsen@mdisecure.com
or
Media Contact:
Michael M. Garcia, 210-477-5400
Mike.Garcia@mdisecure.com
Source: Business Wire (May 4, 2007 - 2:58 PM EDT)
News by QuoteMedia
www.quotemedia.com
MDII - MDI Receives Initial Order for $400,000 from Almana Networks
First Order Issued to MDI Scheduled for August Delivery in Qatar
May 4, 2007 3:47:00 PM
Copyright Business Wire 2007
SAN ANTONIO--(BUSINESS WIRE)--
MDI, Inc. (NASDAQ:MDII), the leading provider of Unified Technology(TM) solutions for the security industry today announced that it has received an order from Almana Networks to provide security products as part of an initial integrated security surveillance project across two building locations, for a major petroleum and natural gas producer's holdings in Qatar. The amount of the order is $400,000 USD, and products are scheduled to be delivered to the client site in August of this year.
As part of the project, MDI will design and develop a complete IP based video surveillance management solution over a TCP/IP network that will provide digital video recording and management within a client-server architecture, allowing for efficient monitoring and recording in a pre-emptive security control environment. The MDI surveillance management solution will include functionality that extends beyond traditional physical security applications by providing real-time risk mitigation and operations management for the client, which is a global leader in the petroleum and natural gas industry.
About MDI, Inc.
MDI (NASDAQ:MDII) manufactures security technology solutions designed to protect people, facilities and assets. These solutions are unified by ONE Technology. ONE Technology unifies security point products, systems and subsystems into a common management platform. Far beyond the Integrated Security Management software promoted by industry competitors, ONE delivers an open architecture environment that adapts each individual application and device into its platform - promoting global collaboration as ONE system. The MDI product family currently protects over 8 million alarm points across the globe for many of the world's most recognized organizations including Microsoft, MBNA Worldwide, John Deere, Pepsi, FBI, TSA, Fidelity Investments, Bureau of Engraving & Printing, American Express, Department of Defense, IRS, Disney, Smithsonian Institution and MIT to name a few. For more information on MDI or its diversified line of security products, please visit www.mdisecure.com.
Forward-Looking and Cautionary Statements
Except for historical information and discussions contained herein, certain statements included in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this document, other than statements of historical fact, that address activities, events or developments that management expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements represent our reasonable judgment on the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "project," "forecast," "plan," "may," "will," "should," "expect" and other words of similar meaning. Investors should not rely on forward-looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the Company's expectation. Additional information concerning risk factors is contained from time to time in the Company's SEC filings. The Company expressly disclaims any obligation to update the information contained in this release.
Source: MDI, Inc.
----------------------------------------------
MDI
Inc.
San Antonio
Investor Relations Contact:
Richard A. Larsen
210-582-2664
Richard.Larsen@mdisecure.com
or
Media Contact:
Michael M. Garcia
210-477-5400
Mike.Garcia@mdisecure.com
EGEI - eGene's HDA-GT12 Genetic Analyzer Demonstrates the Rapid H5N1 Avian Influenza Virus Detection; The System Could Be Developed as an Effective Pathogen Detection Platform
May 4, 2007 12:55:00 PM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--
eGene Inc. (OTCBB:EGEI), developer of a revolutionary high-performance genetic analysis technology, announced today that its HDA-GT12(TM) demonstrates rapid detection of the H5N1 avian influenza virus. The technical article appears in American Biotechnology Laboratory April, 2007 (Vol. 25, No. 5) issue, in the story: "Rapid H5N1 Subtype Avian Influenza Virus Detection." http://www.americanbiotechnologylaboratory.com/articles/index.php?3- all-abl/b0407lee.pdf
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
eGene and the Genome Institute of Singapore (GIS) have worked together to develop a rapid, highly sensitive, and cost-effective screening approach for H5N1 avian influenza virus detection. The HDA system, in combination with the GIS's single-step RT-PCR, is a simple and sensitive assay for H5N1 avian influenza detection that can detect as few as 10 copies of the viral RNA.
"Our system platform provides an efficient way for pathogen detection in molecular diagnostic markets. After the recent merger announcement with Qiagen, we believe the combined companies can accelerate the availability of our technologies into the market and into the hands of more customers and to benefit mankind," said Ming S. Liu, Ph.D., Chief Executive Officer of eGene.
About eGene Inc.
eGene developed the HDA-GT12(TM) (high performance DNA analyzer for genotyping on 12 channels). The system analyzes the genetic fingerprints of living organisms. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of RNA in gene expression market. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzers systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize biomolecules including DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.
Source: eGene Inc.
----------------------------------------------
Martin E. Janis & Company
Inc.
Beverly Jedynak
312-943-1100
ext. 12
bjedynak@janispr.com
more on HLAC...
brand spanking new far as I can tell
http://www.hola-communications.com/
Hola Communications is a new company that was formed to provide wireless broadband access in Northern Mexico.The company’s goal is to be one of the leading providers of broadband wireless access in several metropolitan markets in Northern Mexico, where many international manufacturing plants are located that require a fast, reliable and less expensive broadband alternative. Broadband wireless is the next step in the evolution of corporate connectivity with the roll-out of Intel’s WiMAX technologies.
To connect a business to the Hola Communications network, our technicians will install an integrated transceiver on the roof, in the window, or on the side of the building. They then run a small cable indoors to the customer’s router or firewall. The integrated transceiver transmits data using microwave frequencies to a larger transceiver at one of Hola Communications’s points of presence, or POPs - usually on a tall building.
Carlos Bustamante
Mr. Bustamante is executive vice president of Grupo Bustamante. Grupo Bustamante encompasses a wide array of industries in Baja California, Mexico. Companies within the Group are, real estate development and construction, three industrial parks, two hotels, a cable television channel, a cable television network, a payroll and accounting outsourcing service company, and an aircraft maintenance facility. He is General Director for the three industrial parks consisting of more than 25 buildings (1.5 million sq. ft) with clients such as Lockheed Martin and Plantronics. He also is General Director for Cable California, a start up cable TV Company in the city of Tijuana with more than 3000 homes signed up. He is on the Board of Directors, of two major hotels in the City of Tijuana; he also oversees the new business development activities of the Group. He is currently on the Board of Directors of Grupo Posadas (a nationally owned chain of Fiesta Americana Hotels) and he is a former Vice President of the Tijuana Convention & Visitors Bureau. He is also a member of CANACINTRA (National Chamber of Industry). He belongs to the State Council of Development of Baja California. He is a member of DEITAC (Tijuana Economic Development) as well as a member of AMPIP (Mexican Association of Private Industrial Parks). Carlos is an active member of the board of the Association of Businessmen of Baja California as well.
HLAC - Hola Communications Change of Control and Appointment of New Director
May 4, 2007 12:12:00 PM
Copyright Business Wire 2007
SAN DIEGO--(BUSINESS WIRE)--
Hola Communications Inc. (OTCBB:HLAC) announces that Sean Dickenson has acquired 3,800,000 common shares in the capital stock of the Company in a private transaction pursuant to a share purchase agreement dated May 3, 2007 between Sean Dickenson, Carlos Bustamante and Jose Cerda for the purchase price of US $150,000. Mr. Dickenson now owns 63.3% of the issued and outstanding shares.
We are also pleased to announce the addition of Sean Dickenson to the Board of Directors. Mr. Dickenson will also be acting as President, Chief Executive Officer, Secretary and Treasurer.
Mr. Dickenson is an Independent Financial Consultant involved in the administration of Public Companies with eight years of experience in corporate management and finance.
From September 2006 to present Mr. Dickenson has been a Communications Consultant with Source Petroleum, Inc., from April 2003 to February 2007 he was in charge of Partner Development at Business Objects SA.
From February 2002 to April 2003 Mr. Dickenson was an Investment Advisor with RBC Dominion Securities Inc.
Mr. Dickenson expects to devote approximately fifty per cent (50%) of business time to the operations of the Company.
As of May 3, 2007 Carlos Bustamante has resigned as President and Chief Executive Officer and Jose Cerda has resigned as Secretary and Treasurer.
For more information on Hola Communications Inc. please visit our website: www.hola-communications.com
Source: Hola Communications Inc.
----------------------------------------------
Hola Communications Inc.
Sean Dickenson
604-614-8711
sdickenson@shaw.ca
www.hola-communications.com
FGFC - First Guardian Financial Corporation Announces Positive Development Resulting From Joint Venture Agreement With REMCO-EU / Bulgaria
May 4, 2007 9:54:00 AM
NEW YORK, NY -- (MARKET WIRE) -- 05/04/07 -- First Guardian's (PINKSHEETS: FGFC) Bulgarian Joint-Venture Partner REMCO-EU (REMCO) is a Company dealing in Environmental Upgrading in general and in "Projects From Waste To Energy" in particular. They intensively collaborate with a Scientific Team, out of which several individuals are Members of the Bulgarian Academy of Sciences, to implement supplementary applications out of the produced by-products resulting from treatment of all kinds of wastes applying a US-based state-of-the-art technology.
As it was announced earlier, the European Union (EU) has taken strong commitments towards all problematic situations concerning global warming. One of the related EU Directives 2003/30/EC in accordance to the Commission Green Paper for a European Strategy for the security of energy supply, declares "that all Member States has to set the objective of substitution of 20% of conventional fossil fuels, by environmental friendly alternative fuels for the road transport sector by 2020."
Bulgaria joined the EU in January 2007 and is consequently obliged to take this EU Directive into consideration. Therefore, the Ministry of Energy contacted all companies involved in production of environmental friendly energy and ecological and bio fuels to investigate how much of this required substitution fuels that can be produced and what has to be done to reach the EU quotas.
The Scientific Team of REMCO-EU responded positively and confirmed to the Ministry that up to 10% of the alternate fuel as requested by the EU Directive could be produced by REMCO on the condition that up and about 8,000 MT/day of Municipal Supplied Waste (MSW) would be allocated to REMCO to be treated using Plasma Conversion. The resulting Synthesis Gas as end product of the molecular dissociation of all organic wastes allows commercial justified production of Hydrogen and Ethanol able to fulfill the requirements of the EU Directive and allows Bulgaria to face its responsibility as an EU Member State.
REMCO-EU will now provide a detailed scientific, technical and financial analysis which will be commented on as soon as presented to the Ministry of Energy.
It is essential to notice that making alternate ecological fuels out of organic waste will clean the environment, help reducing CO2 emissions by a minimum of 20% in the sector of transportation and will keep the prices of all kinds of crops affordable in order prevent more famine in the world.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
CONTACT:
First Guardian Financial Corporation
Investor Relations
1-212-363-4333
Fax: 1-212-658-9539
update - AUUM
SCHEDULE 13D
Robert Rich
SOLE VOTING POWER
250,000,000 common shares
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
90.4% based on 276,487,500 common shares issued and outstanding as of April 26, 2007
Item 4. Purpose of Transaction
The purpose of the transaction described above was for Mr. Rich to acquire control of American Uranium Corporation. He has become a director, President, Treasurer and Secretary. Mr. Rich intends to seek other business opportunities for our company unrelated to our current business.
Depending on market conditions and other factors, Mr. Rich may acquire additional shares of the Issuer’s common stock as it deems appropriate, whether in open market purchases, privately negotiated transactions or otherwise. Mr. Rich also reserves the right to dispose of some or all of the Shares in the open market, in privately negotiated transactions to third parties or otherwise.
As of the date hereof, except as described above, Mr. Rich does not have any plans or proposals which relate to or would result in (a) the acquisition by any person of additional securities of the
BIOS - BioScrip, Inc. Reports Significant Increase In Operating Income
May 4, 2007 8:46:00 AM
Copyright Business Wire 2007
ELMSFORD, N.Y.--(BUSINESS WIRE)--
BioScrip, Inc. (NASDAQ: BIOS) today reported a first quarter 106% increase in operating profit over the fourth quarter 2006, on revenues of $296.3 million. First quarter 2007 operating profit was $136,000; EBITDAO (earnings before interest, taxes, depreciation, amortization and option expense) was $3.0 million with a net loss of $1.3 million, or $0.04 per share. This compares to first quarter 2006 revenues of $299.7 million, an operating loss of $1.6 million, EBITDAO of $1.7 million, and a net loss of $1.2 million, or $0.03 per share. The Company adopted FIN 48 effective January 1, 2007. As a result, the Company recorded a $2.4 million tax liability with a corresponding charge to retained earnings.
Chairman and CEO, Richard H. Friedman, stated "Our first quarter 2007 results indicate that we are making substantial progress on our plan of returning BioScrip to profitability. The Company reported a $2.5 million sequential increase in quarterly operating income and increasingly positive EBITDAO which is consistent with our commitment to shareholders."
First Quarter Reported Results
First quarter 2007 Specialty Services revenue was $234.9 million, an increase of $31.3 million, or 15.4% over the prior year, due primarily to revenues associated with preferred distribution arrangements with manufacturers for newly approved drugs, strong growth in infusion and new business resulting from CAP.
First quarter 2007 PBM Services revenue was $61.4 million, a decrease of $34.6 million, or 36.0%, as compared to the first quarter of 2006. The decline in revenue is primarily due to the loss of a major PBM customer previously announced.
As a result, revenue for the first quarter 2007 was $296.3 million compared to $299.7 million for the same period a year ago.
Gross profit for the first quarter 2007 was $32.9 million, or 11.1%, compared to $30.3 million, or 10.1%, for the same period of 2006. Gross margin dollar improvement is primarily due to higher margin Specialty sales.
First quarter 2007 total operating expenses increased by a net $0.9 million to $32.8 million, or 11.1%, of total revenue from $31.9 million, or 10.7%, of total revenue for the first quarter of 2006. The increase is primarily due to ongoing operating expenses associated with the acquisition of our California-based infusion center, operating expense increases related to CAP, and an increase in bad debt expense, partially offset by last year's cost reduction efforts.
CAP Update
First quarter 2007 CAP revenues increased 38% over fourth quarter 2006 to $9.9 million. BioScrip has initiated marketing programs in order to maximize efforts to support the upcoming physician election period which occurs from May 1, 2007 through June 15, 2007 for enrollments effective August 1, 2007
Conference Call Information
BioScrip will host a conference call to discuss first quarter 2007 financial results on Friday, May 4 at 10:00 a.m. EDT. Interested parties may participate in the conference call by dialing 800-266-1825 (US), or 212-676-4900 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available from 12:30 PM EDT on May 4 through 12:30 PM EDT on May 10, by dialing 800-633-8284 (US), or 402-977-9140 (International), and entering reservation #21337474. An audio webcast and archive of the conference call will also be available under the investor relations section of the BioScrip website, www.bioscrip.com.
About BioScrip, Inc.
BioScrip, Inc. provides comprehensive pharmaceutical healthcare solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians and patients to deliver cost effective programs in an effort to optimize the quality of patient life. We focus our products and services in two core areas: Specialty pharmaceutical services, both nationally and community-based, and Pharmacy Benefit Management services. Our specialty services capabilities include condition-specific distribution and clinical management programs for individuals living with health conditions such as HIV/AIDS, cancer, immune deficiency, Hepatitis C, Rheumatoid Arthritis, Multiple Sclerosis, transplantation and Crohn's disease. Our pharmacy benefit management programs include benefit plan design, pharmacy network management and sophisticated reporting capabilities. In addition, we have 36 community, mail service and infusion pharmacies across the U.S., providing nationwide access to prescription medications and clinical services.
Forward Looking Statements
This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.
Earnings before interest, taxes, depreciation, amortization, and option expense ("EBITDAO") is a non-GAAP financial measure as defined under U.S. Securities and Exchange Commission Regulation G. As required by Regulation G, BioScrip has provided a reconciliation of this measure to the most comparable GAAP financial measure.
See Schedule 2 for a reconciliation of the differences between the non-GAAP financial measures and the most directly comparable GAAP financial measures. As required by Regulation G under the Securities Exchange Act, the Company has provided a quantitative comparison between GAAP and disclosed non-GAAP financial measures. The non-GAAP measure presented provides important insight into the ongoing operations and a meaningful benchmark to evidence the Company's trend towards a return to profitability.
Schedule 1
BIOSCRIP, INC.
CONSOLIDATED STATEMENT of OPERATIONS
(in thousands, except per share data)
Three Months Ended
March 31,
-------------------
2007 2006
-------------------
Revenue $296,342 $299,718
Cost of revenue 263,394 269,388
--------- ---------
Gross profit 32,948 30,330
% of revenue 11.1% 10.1%
Selling, general and administrative expenses 28,369 27,886
Bad debt expense 2,996 2,299
Amortization of intangibles 1,447 1,622
Merger related expenses - 131
--------- ---------
Total operating expenses 32,812 31,938
% of revenue 11.1% 10.7%
Income (loss) from operations 136 (1,608)
Interest expense, net (1,085) (450)
--------- ---------
Loss before income taxes (949) (2,058)
Provision for (benefit from) income taxes 398 (902)
--------- ---------
Net loss ($1,347) ($1,156)
========= =========
Basic net loss per share ($0.04) ($0.03)
Diluted net loss per share ($0.04) ($0.03)
========= =========
Basic weighted-average shares 37,490 37,202
Diluted weighted-average shares 37,490 37,202
========= =========
Schedule 2
BIOSCRIP, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(in thousands)
Three Months Ended
March 31,
------------------
2007 2006
------------------
Income (loss) from operations $136 ($1,608)
Addback items:
Depreciation 1,044 1,042
Amortization of intangibles 1,447 1,622
SFAS 123R stock option expense 342 645
--------- --------
Earnings before interest, taxes, depreciation,
amortization and stock option expense (EBITDAO) $2,969 $1,701
========= ========
Schedule 3
BIOSCRIP, INC
CONSOLIDATED BALANCE SHEET
(in thousands, except share and per share data)
March 31, 2007
(unaudited) December 31, 2006
ASSETS
Current assets
Cash and cash equivalents $1 $-
Receivables, less allowance for
doubtful accounts of $12,612
and $13,774 at March 31, 2007
and December 31, 2006,
respectively 136,095 135,139
Inventory 36,616 33,471
Prepaid expenses and other
current assets 4,845 2,090
-------------- -----------------
Total current assets 177,557 170,700
Property and equipment, net 10,160 10,409
Other assets and investments 464 681
Goodwill 114,824 114,991
Intangible assets, net 7,228 8,675
-------------- -----------------
Total assets $310,233 $305,456
-------------- -----------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Line of credit $50,185 $52,895
Accounts payable 52,669 51,724
Claims payable 14,611 9,548
Payables to plan sponsors 590 589
Payor Allowance 10,492 9,691
Accrued expenses and other
current liabilities 8,697 9,230
-------------- -----------------
Total current liabilities 137,244 133,677
Unrecognized tax benefits 4,070 -
Deferred taxes, net 10,663 9,946
-------------- -----------------
Total liabilities 151,977 143,623
-------------- -----------------
Stockholders' equity
Preferred stock, $.0001 par
value; 5,000,000 shares
authorized, no shares issued or
outstanding - -
Common stock, $.0001 par value;
75,000,000 shares authorized;
shares issued: 40,859,726 and
40,680,233 respectively; shares
outstanding: 37,492,757 and
37,488,257, respectively; 4 4
Treasury stock, 2,247,150 shares
at cost (8,002) (8,002)
Additional paid-in capital 239,506 239,315
Accumulated deficit (73,252) (69,484)
-------------- -----------------
Total stockholders' equity 158,256 161,833
-------------- -----------------
Total liabilities and
stockholders' equity $310,233 $305,456
-------------- -----------------
Source: BioScrip, Inc.
----------------------------------------------
BioScrip
Inc.
Craig Allison
914-460-1636
Investor Relations
callison@bioscrip.com
wow..dat b nice
PTSC - Patriot Scientific Announces Nokia Purchase of Moore Microprocessor Patent(TM) Portfolio License
May 3, 2007 3:47:00 PM
CARLSBAD, Calif., May 3 /PRNewswire-FirstCall/ -- Patriot Scientific Corporation (OTC Bulletin Board: PTSC) confirmed today that Nokia, a world leader in mobile communications, has purchased a Moore Microprocessor Patent(TM) (MMP) Portfolio license. Patriot Scientific and The TPL Group are co-owners of the MMP Portfolio, which Alliacense, a TPL Group enterprise, exclusively manages.
"The feature richness of mobile phones would not be possible without exploiting the design techniques engendered by the MMP Portfolio," said Mike Davis, Alliacense senior VP of licensing. "Such techniques are fundamental in the design of microprocessors and enable higher performance and lower cost in a host of digital products ranging from mobile phones and portable music players to communications infrastructure and medical equipment to automobiles, which today deploy dozens of microprocessors."
Nokia is the 17th company to join the distinguished roster of global manufacturers that have captured early-mover MMP licensing berths in specific industry segments since January 2006. Alliacense again confirmed that subsequent licensees in segments where early tiers have been secured are subject to progressively higher royalty rates on relevant products.
"As co-owner of the MMP Portfolio we are pleased to welcome Nokia as the newest addition to the growing list of global companies participating in the MMP Portfolio Licensing Program," said David Pohl, chairman and CEO of Patriot Scientific Corporation. He noted that HP, Casio, Fujitsu, Sony, Nikon, Seiko Epson, Pentax, Olympus, Kenwood, Agilent, Lexmark, Schneider Electric, NEC Corporation, Funai Electric, SanDisk and Sharp Corporation have purchased MMP Portfolio licenses. Intel and AMD are also licensees.
Pohl noted that the strong momentum of the licensing program validates the decision by Patriot's board of directors in June 2005 to shift the company's primary business model from manufacturing and marketing products to a model currently focused primarily but not exclusively on licensing their joint venture MMP patent portfolio. He emphasized that Patriot Scientific invested millions of dollars and hundreds of thousands of man-hours over 12 years or more developing and bringing to market products based upon the company's intellectual property, including IP contained in the MMP Portfolio.
"As evidenced by information in our recent quarterly report and presented at our annual meeting of shareholders last week, we are continuing to seek and evaluate opportunities to diversify our revenue stream by developing and marketing new technologies, entering into joint ventures or by acquiring other companies and technologies," Pohl stated. "We are always focused on the goal of increasing the financial position and strength of the company and providing value to our shareholders."
About Nokia
Nokia is a world leader in mobile communications, driving the growth and sustainability of the broader mobility industry. Nokia connects people to each other and the information that matters to them with easy-to-use and innovative products like mobile phones, devices and solutions for imaging, games, media and businesses. Nokia provides equipment, solutions and services for network operators and corporations. Further information is available at www.nokia.com
About Patriot Scientific
Patriot Scientific is a leading intellectual property licensing company that develops, markets and enables innovative technologies to address the demands in fast-growing markets such as wireless devices, smart cards, home appliances and gateways, set-top boxes, entertainment technology, automotive telematics, biomedical devices and industrial controllers. Headquartered in Carlsbad, Calif., information about the company can be found at http://www.ptsc.com.
Copies of Patriot Scientific press releases, current price quotes, stock charts and other valuable information for investors may also be found at http://www.hawkassociates.com, http://www.americanmicrocaps.com, and at www.agoracom.com/IR/Patriot, in addition to the company's web site.
About the Patent Portfolio
The patent portfolio, marketed as the Moore Microprocessor Patent(TM) Portfolio, is jointly owned by the publicly held Patriot Scientific Corporation and the privately held TPL Group. The portfolio encompasses seven U.S. patents as well as their European and Japanese counterparts fundamental to the design of modern microprocessors, microcontrollers, Digital Signal Processors (DSPs), embedded processors and System-on-Chip (SoC) implementations.
About Alliacense
Alliacense is a TPL Group Enterprise executing best-in-class design and implementation of Intellectual Property (IP) licensing programs. As a cadre of IP licensing strategists, technology experts, and experienced business development /management executives, Alliacense focuses on expanding the awareness and value of TPL's IP portfolios. Founded in 1988, The TPL Group has emerged as a global coalition of high technology enterprises involved in the development, management and commercialization of IP assets as well as the design, manufacture and sales of proprietary products based on these same IP assets. For more information, visit www.alliacense.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, seasonality and other risk factors detailed in the company's Securities and Exchange Commission filings.
Moore Microprocessor Patent (MMP) and Alliacense are trademarks of Technology Properties Limited (TPL). PTSC and Ignite are trademarks of Patriot Scientific Corporation. All other trademarks belong to their respective owners.
CONTACTS:
Patriot Investor Relations:
Hawk Associates, Frank Hawkins or Ken AuYeung (305) 451-1888
info@hawkassociates.com
AGORACOM Investor Relations, PTSC@Agoracom.com
www.agoracom.com/IR/Patriot
Patriot Media Relations: The Hoffman Agency, John Radewagen,
(408) 975-3005 jradewagen@hoffman.com
Alliacense Media Relations: Tom Rigoli, Mindpik, (650) 969-5986
rigoli@mindpik.com
SOURCE Patriot Scientific Corporation
----------------------------------------------
Patriot Investor Relations: Hawk Associates
Frank Hawkins or Ken AuYeung
+1-305-451-1888
info@hawkassociates.com; or AGORACOM Investor Relations
PTSC@Agoracom.com; or Patriot Media Relations: The Hoffman Agency
John Radewagen
+1-408-975-3005
jradewagen@hoffman.com; or Alliacense Media Relations: Tom Rigoli
Mindpik
+1-650-969-5986
rigoli@mindpik.com
MDII - MDI and Almana Networks Partner to Service Rapidly Growing Security Market in Qatar
Joint Venture Scheduled to Deliver $1M in Orders to MDI During First Month of Operation
May 3, 2007 12:49:00 PM
Copyright Business Wire 2007
SAN ANTONIO--(BUSINESS WIRE)--
MDI, Inc. (NASDAQ:MDII), the leading provider of Unified Technology(TM) solutions for the security industry, today announced that it has entered into a joint venture agreement with Doha, Qatar based Almana Networks. The agreement establishes a joint venture between the two parties focused on providing unified physical and electronic security solutions, along with converged network infrastructures, to existing organizations and new construction projects in the rapidly growing country of Qatar.
The Almana Group is one of the largest business organizations in the country and is a significant contributor to its continued economic development and financial infrastructure. Its subsidiary business divisions include oil and natural gas, general contracting, steel production, transportation, retail, restaurants, information technology, financial services, real estate, engineering, HVAC systems, automobiles and marine services.
The new venture is currently finalizing negotiations on several security projects in Qatar, two of which it believes it will be awarded during the month of May. These multi-million dollar comprehensive projects include over one million dollars in products and services from MDI when finalized. They include securing new construction developments for a global leader in the petroleum and natural gas industry and securing regional holdings for one of the most prestigious hotel chains in the world.
"Almana Networks and MDI are both proven leaders in their respective countries," stated Swaraj Kumar, Chief Executive Officer of Almana Networks. "MDI's technology offerings and security expertise will play a critical role in the growth strategy for Almana Networks and I look forward to working with the MDI Team on this new venture to provide state-of-the-art automated security solutions via converged networks to our valued customers in Qatar," he added.
Among the wealthiest countries in the world, Qatar is experiencing phenomenal growth in both oil and non-oil related business sectors. Amid the current economic boom, commercial and industrial construction is at an all time high. In the city of Doha alone, there are currently over 50 hi-rise building sites under construction. The country is well on its way to becoming the world's top petrochemicals producer and is diversifying into many new industries including steel, concrete and aluminum production.
High economic and demographic growth and the changing international security environment have made Qatar more security-conscious. There has been a noticeable increase in the need for security products and services for both private and government establishments, thus the demand for best-in-class security solutions is at an all time high. Both are upgrading the capabilities of existing security systems as well as adding security to new projects in order to keep ahead of changing global security situations. Consumers across the Gulf States Region hold the security sector expertise of the United States in high regard.
The Joint Venture between MDI and Almana Networks was designed to provide customized solutions to the direct needs of Qatar. Together, the strength of the venture combines the following unique points:
-- A deep understanding of the political and economic structure
of Qatar and the Gulf States Region
-- A global business network built on over forty years of
business to business commerce across multiple market verticals
-- The existence of immediate multi-year, multi-million dollar
business opportunities in Qatar
-- A broad portfolio of information technology and business
process services including computer networks, technology
infrastructures, databases and software development
-- Expertise in Internet security, information assurance and
computer network security via partnership with SureSEC, Ltd.
-- Over 25 years of experience in securing classified,
high-security facilities as the solution of choice for the
United States Government
-- Unification of the command & control process within a global
security enterprise including access control, video
surveillance, intrusion detection, biometrics, detection
sensors and third party security point products
-- A professional services organization with complete program
management capabilities and the security industry expertise
necessary to successfully deploy complex security strategies
worldwide.
"As announced last year, MDI has been focusing on several opportunities in the Middle East with its new Global Systems Solutions subsidiary," stated J. Collier Sparks, President and CEO of MDI, Inc. "This joint venture is one result of that focus. By partnering with one of the most successful and respected business organizations in Qatar, MDI is now positioned to capitalize on a multi-billion dollar market that many will strive for but few will succeed in due to the vast barriers to entry. This is a tremendous milestone for the company and its stakeholders and I am proud that MDI has been selected as Almana's exclusive physical solution provider in the region," he concluded.
About The Almana Group
The Almana Group is one of the largest business organizations in Qatar. Since its inception in 1960, it has grown in strength and size and in the process has made significant contributions to the very infrastructure of Qatar. Today, with over 1500 employees, the group boasts a large and diversified portfolio and is poised to participate successfully in the ongoing economic growth and development of the country. Through re-investment of profits, recruitment of the highest skilled managers and the creation of joint ventures with major international companies, the group is able to provide professional services to overseas companies with interests in building their business in Qatar and the Arabian Gulf States. For more information about The Almana Group, please visit www.almanagroup.com.
About SureSEC, Ltd.
SureSEC Ltd. is a global leader in providing Internet security solutions, information security research and professional consulting. The company's security experts have pioneered the field of security and vulnerability research and work closely with many of the world's leading software companies and service providers to discover critical vulnerabilities in their products and provide risk mitigation strategies. SureSEC also consults with numerous open source software companies and well-known Linux providers to deliver source code auditing and technical expertise that is un-matched in the industry. The SureSEC security research team is located across Europe, the United States and the Middle East. For more information on the company and its capabilities, please visit www.suresec.org.
About MDI, Inc.
MDI (NASDAQ:MDII) manufactures security technology solutions designed to protect people, facilities and assets. These solutions are unified by ONE Technology. ONE Technology unifies security point products, systems and subsystems into a common management platform. Far beyond the Integrated Security Management software promoted by industry competitors, ONE delivers an open architecture environment that adapts each individual application and device into its platform -- promoting global collaboration as ONE system. The MDI product family currently protects over 8 million alarm points across the globe for many of the world's most recognized organizations including Microsoft, MBNA Worldwide, John Deere, Pepsi, FBI, TSA, Fidelity Investments, Bureau of Engraving & Printing, American Express, Department of Defense, IRS, Disney, Smithsonian Institution and MIT to name a few. The company has received numerous industry awards for their security technology including Frost & Sullivan's Security System Technology Leadership Award and the Security Industry Association's Best Integrated Product Award for 2006. For more information on MDI or its diversified line of products and professional services, please visit www.mdisecure.com.
Forward-Looking and Cautionary Statements
Except for historical information and discussions contained herein, certain statements included in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this document, other than statements of historical fact, that address activities, events or developments that management expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements represent our reasonable judgment on the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "project," "forecast," "plan," "may," "will," "should," "expect" and other words of similar meaning. Investors should not rely on forward-looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the Company's expectation. Additional information concerning risk factors is contained from time to time in the Company's SEC filings. The Company expressly disclaims any obligation to update the information contained in this release.
Source: MDI, Inc.
----------------------------------------------
MDI
Inc.
San Antonio
Investor Relations Contact:
Richard A. Larsen
210-582-2664
Richard.Larsen@mdisecure.com
or
Media Contact:
Michael M. Garcia
210-477-5400
Mike.Garcia@mdisecure.com
GSHF - GreenShift Portfolio Company Sterling Planet Partners with PepsiCo on Purchase of Renewable Energy Certificates
May 3, 2007 12:24:00 PM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
GreenShift Corporation (OTC Bulletin Board: GSHF) today announced that its Sterling Planet, Inc. portfolio company entered into an agreement with PepsiCo to purchase renewable energy certificates to offset 100% of the purchased electricity used by all PepsiCo US Facilities.
Marking the largest REC purchase to date, the purchase matches the purchased electricity used by all PepsiCo US-based manufacturing facilities, headquarters, distribution centers and regional offices.
"Energy is a key focus for PepsiCo within its environmental sustainability agenda," said John Compton, chief executive officer, PepsiCo North America. "The purchase of these RECs is not only in line with our progress to date, but further advances our commitment to sustainability and helps make a positive impact in the communities we serve across the country."
Green power is produced from renewable resources such as solar, wind, geothermal, biogas, biomass and low-impact hydro. These energy sources are considered cleaner and have a superior environmental profile than conventional sources of electricity. Purchasing RECs helps drive the development of additional renewable energy capacity nationwide.
PepsiCo's three-year purchase is comprised of more than 1 billion kilowatt-hours annually. Based on national average emissions rates, the U.S. EPA estimates PepsiCo's purchase is the same amount of electricity needed to power nearly 90,000 average American homes annually.
With this purchase PepsiCo tops EPA's list of top-25 green power purchasers, as well as becoming the top Fortune 500 purchaser. PepsiCo also becomes a member of the EPA's Green Power Partnership, which is comprised of organizations that voluntarily purchase green power as a way to reduce the environmental impacts associated with conventional electricity use.
"America is shifting to a 'green culture,' with more and more businesses understanding that environmental responsibility is everyone's responsibility," said EPA Administrator Stephen L. Johnson. "By switching to alternative, renewable power sources, PepsiCo is proving that going green can be the choice of every generation."
PepsiCo, which formed its Environmental Task Force in 2001, and its divisions are actively involved in a variety of environmental initiatives and have been recognized for their efforts. For example, Frito-Lay and Gatorade operate two LEED GOLD certified facilities. The US Green Buildings Council LEED Rating System is the nationally accepted benchmark for evaluating sustainable sites, water efficiency, energy and atmosphere efficiency, material and resource selection and indoor environmental quality. Tropicana's Ft. Pierce facility has partnered with St. Lucie County to burn landfill gas, a renewable energy source that displaces the use of natural gas, in its boiler.
Earlier this year PepsiCo was recognized as ENERGY STAR Partner of the Year for outstanding energy management and reductions in greenhouse gas emissions. PepsiCo's Frito-Lay North America division received the award in 2006.
PepsiCo is partnering with Sterling Planet on the purchase of the RECs. Sterling Planet, a leading retail provider of renewable energy, is identifying and acquiring the RECs for PepsiCo. The company will seek to source the RECs to model PepsiCo's purchased electricity use geographically.
"We are pleased to join with PepsiCo to make history with this largest-ever purchase of clean, renewable energy certificates. Sterling Planet will be working closely with PepsiCo to support the strategic decision to match the RECs to their geographic use of electricity in the U.S.," said Mel Jones, president and chief executive officer, Sterling Planet. "This approach should help the local communities where PepsiCo has a presence to grow local renewable energy sources."
The Green-e program, administered by the Center for Resource Solutions (CRS), will certify that the RECs meet stringent environmental guidelines and will verify that the renewable energy credits being purchased for PepsiCo are retired on PepsiCo's behalf. CRS is a national non-profit organization working to promote sustainable resource solutions that reduce greenhouse gas emissions responsible for climate change.
"PepsiCo is demonstrating environmental leadership and innovation while inspiring other U.S. corporations to take action," said Dan Lieberman, Green-e program manager, Center for Resource Solutions. "This type of commitment from PepsiCo makes tremendous strides toward a clean, renewable energy future for all Americans."
PepsiCo is one of the world's largest food and beverage companies, with 2006 annual revenues of more than $35 billion. Its principal businesses include: Frito-Lay snacks, Pepsi-Cola beverages, Gatorade sports drinks, Tropicana juices and Quaker foods. Its portfolio includes 17 brands that generate $1 billion or more each in annual retail sales.
About the U.S. EPA's Green Power Partnership
EPA's Green Power Partnership encourages organizations to purchase green power as a way to reduce the environmental impacts associated with conventional electricity use. The Green Power Partnership currently has hundreds of Partners voluntarily purchasing billions of kilowatt hours of green power annually. Partners include a wide variety of leading organizations such as Fortune 500 companies, small and medium sized businesses, local, state, and federal governments, trade associations, as well as colleges and universities. For additional information, please visit http://www.epa.gov/greenpower.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of GreenShift Corporation, and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Source: GreenShift Corporation
----------------------------------------------
GreenShift Corporation
Phone: 212-994-5374
Fax: 646-572-6336
Email: investorrelations@greenshift.com
Web: www.greenshift.com
or
Investor Relations:
CEOcast
Inc.
Andrew Hellman
Phone: 212-732-4300
or
Public Relations:
Walek & Associates
Deborah McCandless
Direct: 212-590-0523
Fax: 212-889-7174
E-mail: dmccandless@walek.com
Web: www.walek.com
BTMD - BioTech Medics Developing Avian Bird Flu Virus Prevention Program
May 3, 2007 10:03:00 AM
DALLAS, TX -- (MARKET WIRE) -- 05/03/07 -- BioTech Medics, Inc., (PINKSHEETS: BTMD) announced they are contacting various foreign government representatives advising them of BioTech's clinically proven SHBAN Solution which kills the Avian Bird Flu Virus on contact as a topical solution to help prevent the spread of the virus among humans and birds.
The clear superiority of SHBAN over other hand sanitizers is that SHBAN is longer-lasting as it puts a non-toxic film on your hands and it does not evaporate after application (compared to alcohol based hand sanitizers). SHBAN is non-bleaching and has no toxic odors. Additionally, the SHBAN 3oz. size is convenient to carry in a purse, briefcase, backpack, waist pouch or vehicle.
SHBAN can also be used in bulk to spray in poultry farms directly on the birds, ground and cages to help kill the disease without harming the birds (when used as directed). SHBAN has a 99% effective rate in killing the Avian virus upon contact, compared to a 45% effective rate of a series of drugs currently being used to inoculate birds in an attempt to protect them.
The SHBAN(TM) solution was tested at the University of London, Queen School of Medicine, Retroscreen Labs against the H5N1 virus. In previous in vitro and in vivo testing SHBAN has been evaluated for its antimicrobial properties against S. Aureus, S. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Tests revealed that SHBAN was extremely effective against all species of bacteria that were tested. SHBAN has previously been tested by Baylor Medical Center in Houston, Louisiana State University, UT Houston, Allergan, Pathology Associates, MBA Labs and Texas A&M College of Veterinary Medicine. SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711. #5,585,391. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.
Safe Harbor for Forward-Looking Statements.
This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has not evaluated SHBAN and has not expressed an opinion regarding any claims made. SHBAN is not for the diagnosis, treatment and/or cure of any disease.
Contact:
BTMD
Investor Relations
1-800-200-2458
NWMO - New Motion, Inc. Announces Name Change from MPLC, Inc., New Ticker Symbol 'NWMO', and Reverse Stock Split
New Motion, Inc. (OTCBB:NWMO), formerly MPLC, Inc. announced today that the name of the Company has been changed from MPLC, Inc. to New Motion, Inc. and that the Company completed a 1−for−300 reverse split of the Company's common stock. Concurrent with the reverse split, all classes of the Company preferred stock converted, on a mandatory basis, into shares of common stock. As a result of the reverse split and the conversion of preferred stock, as of May 3, 2007, the Company has approximately 11,680,000 shares of common stock issued and outstanding.
The post−reverse−stock−split common stock of the Company began trading May 3, 2007 on the NASD Over−The−Counter Bulletin Board under the new ticker symbol "NWMO".
About New Motion, Inc.
New Motion, Inc. (OTCBB:NWMO), is a digital entertainment company providing a broad range of digital and mobile products and services to consumers. New Motion, Inc. combines the power of the Internet, the latest in mobile technology, and traditional marketing / advertising methodologies to their brands: MobileSidewalk™, a mobile entertainment portal, RingtoneChannel, a mobile storefront provider, Bid4Prizes, a low-bid mobile auction game, and GatorArcade, a premium online and mobile gaming site. Headed by a seasoned team of Internet, new media, entertainment and technology professionals, New Motion, Inc. was founded in 2005 and is headquartered in Irvine, California with a branch office in Los Angeles. Wired Magazine recently declared New Motion’s mobile content capabilities a “rival to those of their mainstream-media counterparts,” Wireless Business Forecast named New Motion “a company to watch,” and RCR Wireless News noted that New Motion, Inc. is “gaining traction in the direct-to-consumer ring.” For more information, please visit www.newmotioninc.com, www.mobilesidewalk.com, www.ringtonechannel.com, www.bid4prizes.com or www.gatorarcade.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, about New Motion. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of New Motion’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: changing interpretations of generally accepted accounting principles; continued compliance with government regulations; legislation or regulatory environments, requirements or changes adversely affecting the businesses in which New Motion engaged; demand for the products and services that New Motion provides, general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in New Motion’s filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. New Motion assumes no obligation to update the information contained in this press release.
New Motion, Inc.
Allan Legator, Chief Financial Officer and Secretary
949-777-3700
or
Investor:
Dean Oakey, 213-253-2282
or
Media:
Karen Strickholm, 505-988-4401
StrickholmCompany@msn.com
Source: Business Wire (May 3, 2007 - 9:07 AM EDT)
News by QuoteMedia
www.quotemedia.com
FEKY - FaceKey Patent for a Fingerprint Verification System Issued
May 3, 2007 9:41:00 AM
Copyright Business Wire 2007
SAN ANTONIO--(BUSINESS WIRE)--
FaceKey Corporation, (Pink Sheets: FEKY) the manufacturer of biometric-based ID management products for access control, time and attendance and muster stations, announced today that their patent application, US 7,212,655 B2, for a fingerprint verification system, was issued Tuesday, May 1, 2007.
This patent builds on a previously issued FaceKey patent, US 6,963,659 B2, which established the software basis for searching a large database of authorized users using two biometric identifiers. The most recent patent will strengthen FaceKey's position in the marketplace by allowing us to serve larger customers, such as large corporations and government agencies with ID management products based on off the shelf hardware that do not require a non-biometric identifier such as a card or a PIN.
"FaceKey is extremely excited about this new patent for a number of reasons; it will lower the cost of security, it will be easier to use and have fewer errors than traditional security systems, and it will work with existing hardware platforms making implementation, training and use much easier. In addition, there will be many licensing opportunities available for qualified manufacturers," stated Dr. Yevgeny B. Levitov, President of FaceKey.
About FaceKey Corporation
FaceKey Corporation, a development stage company, engages in the manufacture and sale of security equipment for home and business which utilize biometric technologies, i.e. fingerprint and/or facial recognition, for identification. In addition, the company has built a portfolio of patents related to fingerprint and/or facial recognition which is available for licensing to others for integration into products to provide genuine ID(TM). Its products are sold through a network of distributors, dealers and system integrators worldwide. The company was co-founded by Yevgeny B. Levitov and Annette H. Starkweather in 1999 and is based in San Antonio, Texas.
Forward-Looking Statements
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of FaceKey Corporation and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
FOR INVESTOR INQUIRIES: Please visit the Company's website, www.facekey.com, or contact: Annette Starkweather, 210-826-8811.
Source: FaceKey Corporation
----------------------------------------------
FaceKey Corporation
Annette H. Starkweather
210-826-8811
www.facekey.com